Turkey: Way To A New Era For Clinical Trials In Turkey

Last Updated: 31 August 2011
Article by E. Sevi Firat

Legal aspect of clinical trials occupies the agenda of medical and pharmaceutical sector as of the cancellation action filed by the Turkish Medical Association ("TMA") in March 2009 against certain provisions of the Regulation Pertaining to Clinical Trials dated 2008 ("Regulation"). In course of time, legal grounds of the clinical trial legislation became subject to a profound debate.

The 10th Chamber of Council of State, who examined the action, ruled on stay of execution of some articles of the Regulation in November 2009 due to miscellaneous reasons, such as payment shall not be done to the volunteers as a result of their participation in clinical trials and they shall be informed and enlightened by a person who is independent from the research team; concurrent applications shall not be made to Ethical Committees and General Directorate of Pharmaceuticals and Pharmacy and it is not possible for the changes in protocols become effective unless such are approved; the impossibility of establishment of constant committees, namely Ethical Committees and Clinical Trials Consultative Committee by a regulation, such shall only be established by a law or under the authority of the High Council of Health. The Council of State, with this interlocutory stay of execution decision, prevented implementation of these provisions until a final decision is rendered on merits of the action and proceeded with the next examination stage in order to reach a final decision.

Upon this decision, the Ministry of Health ("MoH"), without waiting for finalization of the pending action, chose to constitute ethical committees within the scope of the High Council of Health by reflecting the above mentioned alterations to the Regulation on March 11, 2010. On the other hand, both the MoH and TMA filed a review request with the Plenary Session of the Chambers for Administrative Cases of the Council of State ("PSCAC") being the higher chamber of the 10th Chamber.

The review decision that was rendered by PSCAC in July 2010 initiated hot debates. With this decision, the decision of the 10th Chamber of Council of State is taken one step forward. It is underlined that the Regulation was directly related to right to life and immunity of physical integrity, which are among primary fundamental human rights, and the trials in scope of the Regulation constitute intervention to immunity of physical integrity, this basic human right could only be limited by law even in case of existence of subject's consent and it would be against the Constitution that a person be subject to scientific and medical experiments unless authorized by law. This decision gave rise to the interpretation that the Regulation became invalid from a legal aspect. Upon this decision, the MoH ceased accepting trial applications on October 1st, 2010 and this led to concerns with regard to the status of the ongoing trials.

Consequently, leading universities in clinical trials decided to take the required steps in order to continue clinical trials and constituted independent Ethical Committees within their scope by adopting the interpretation that universities are granted authority by the Higher Education Law to conduct scientific trials including clinical trials. And upon this development MoH announced that they continue accepting clinical trial applications.

In May 2011, the 10th Chamber of Council of State delivered its final judgment on the action. In this decision, contrary to PSCAC, it is accepted that the MoH has appropriate legal grounds to regulate clinical trials and the rules regarding clinical trials could be set forth under a legal text with the force of a regulation1. In April 2011 the TMA appealed the decision and appeal application is still under examination of the PSCAC. However, considering below summarized developments, the final decision is expected to be in direction of an approval of the decision of the 10th Chamber.

On the other hand, it is not ignored that the aforesaid developments have given rise to the necessity to enact a law in order to maintain an appropriate and legitimate background for the conduct of clinical trials and enactment procedures are initiated rapidly. By way of adding an article ("Law") to the Principal Law on Health Services no. 3359 on April 6, 2011 that appropriate legal ground was provided. This provision, which contents with drawing the general frame of clinical trials, leaves the details to be set forth by the MoH through issuing regulations.

Following the entry into force of the Law, the MoH acted quickly and issued a new clinical trial regulation ("the New Regulation") on August 19, 2011 which is based on the Law and the international treaties that Turkey is a party to, such as Helsinki Declaration.

Henceforward clinical trials in Turkey shall be conducted in compliance with below stated principles pursuant to the Law and the New Regulation:

  • Even though such is not explicitly stated within the Regulation, it could be inferred from joint interpretation of the relevant articles that it is not possible to carry out clinical trials in private hospitals, and only universities, education and research hospitals and other governmental hospitals and health centres can be appointed as trial institutions.
  • Either the pharmaceutical company that is to conduct the clinical trial (Sponsor) or the Contract Research Organization (CRO) that is assigned by this company shall be resident in Turkey.
  • Clinical trials on human beings with medicinal products and combinations, even though registered or permitted, observational studies on medicinal products, observational studies on medical devices; clinical trials with all other ingredients or products which can be conducted in humans, including medical devices, advanced therapy products, traditional herbal medicinal products, cosmetic raw materials or products; bioavailability and bioequivalence studies, comparability studies for biosimilar products, studies to be conducted on industrial advanced medical products and non-industrial advanced medical products, studies on stem cell transplant on humans, studies on organ and tissue transplant, surgical studies, gene therapy studies, as well as the clinical trial sites and physical or legal persons conducting clinical trials are all subject to the New Regulation.
  • The non-invasive clinical trials, else then the ones defined as observational studies, are left out of the scope of the Regulation and except from those, approval of the Ethical Committee is required for all of the above stated studies. However, due to some inconsistent wording in the New Regulation, definition of non-invasive still needs to be clarified.
  • The Ethical Committees are grouped into three as "Pharmaceutical", "Non-Pharmaceutical" and "Bioavailability/Bioequivalence (BA/BE)" Clinical Trials Ethical Committees. 2
  • Prior to the approval of the Ethical Committee; the issues such as objective of the trial; expected benefit, analysis of risks and damages; trial brochure; obtainment of consents of volunteers; insurance covering the researcher or sponsor and volunteer; research team; trial budget and places where the trial will be conducted shall be clarified.
  • It is possible to inform and enlighten the volunteer by a member of the research team in course of obtaining the consent of the volunteer.
  • During Ethical Committee approval phase, the Committee is permitted to request correction from the Sponsor or CRO only once and thus the approval procedure is aimed to be shortened.
  • Upon approval of the Ethical Committee, it shall be applied to the relevant general directorate of the MoH in order to obtain trial permission after filling the forms and preparing the annexes published and required by the MoH.
  • A pharmacist shall be assigned for storage, distribution, delivery, destruction of the trial product pursuant to the New Regulation; it is foreseen that the responsible pharmacist shall be notified during the course of the approval application before MoH.
  • Following the approval of the MoH, the trial is expected to be conducted in line with the Law, New Regulation and the relevant guidelines.

Another recent development regarding clinical trials is the new Medical Device Regulation which is published in the Official Gazette and entered into force on June 7, 2011.

Article 15 of the Medical Device Regulation sets forth special provisions regarding medical device clinical trials while the Regulation Pertaining to Clinical Trials envisages general provisions for all types of clinical trials including medical device trials. The Medical Device Regulation can be deemed as an exact adoption of the EU Directive no. 93/42/EEC in general view.

Issuance of new rules for medical device clinical trials, while the Regulation Pertaining to Clinical Trials covering medical devices is still in force, give rise to questions regarding which set of rules has priority of implementation. Considering that there are huge legal gaps concerning clinical trials in the Medical Device Regulation such as details of the Ethical Committee approval procedure, the principles regarding the protection and insurance of trial subjects, the details of the ICF, the standards of the places where the trial will be conducted, the specifics of the trial approval of the MoH, the conduct of the trial, the responsibilities of the parties, the import of the trial product, adverse event reporting etc., the Regulation Pertaining to Clinical Trials still remains as an important and effective guide for the conduct of the medical device trials. Also, from a legal point of view, as the New Regulation Pertaning to Clinical Trials is published at a later date, it shall prevail over the rules set forth under the Medical Device Regulation as far as there is a contradiction between the same.

Since the medical device clinical trial related provisions are recent and unimplemented, changes in the latter are expected upon practice. However, at first glance, the below stated principles seem to be in force in order to conduct a medical device trial;

  • The objective of a medical device clinical trial shall be to verify that under normal conditions of use, the performance of the devices conform to those referred to in Annex I of the Medical Device Regulation, and to determine any undesirable side-effects, under normal conditions of use, and to assess whether they constitute risks when weighed against the intended performance of the device.
  • In case the clinical trial is conducted using a medical device bearing CE marking for the purpose that is referred to in the relevant conformity assessment procedure, only the provisions of Annex X of the Medical Device Regulation which are in line with the EU rules are applicable.
  • Prior to applying to the MoH for approval, Ethical Committee approval shall be obtained in accordance with the new Regulation Pertaining to Clinical Trials.
  • In accordance with Article 15 of the Medical Device Regulation, manufacturer or its authorized representative should prepare a declaration consisting of the data allowing identification of the device in question, a trial plan, investigator brochure, undertaking of insurance coverage for trial subjects, informed consent form, statement whether any substance included in Annex I/7.4 of the Medical Device Regulation or human blood derivatives is contained in the device, whether animal based tissues are used in the device, the opinion of the Ethical Committee concerned and details of the aspects covered by its opinion, the name of the medical practitioner or other authorized person and of the institution responsible for the trial, the place, starting date and scheduled duration for the trial, statement that the device in question conforms to the essential requirements apart from the aspects covered by the trial and that, with regard to these aspects, every precaution has been taken to protect the health and safety of the patient. It should be noted that the manufacturer declaration to be filed to the MoH consists of a broader and more detailed document when compared with the declaration envisaged in the EU Directive.
  • Clinical trials must be performed on the basis of an appropriate trial plan reflecting the latest scientific and technical knowledge and defined in such a way to confirm or refute the manufacturer's claims for the device; these trials must include an adequate number of observations to guarantee the scientific validity of the conclusions.
  • The procedures used to perform the trials must be appropriate to the device under examination and must be performed in circumstances similar to the normal conditions of use of the device. All the appropriate features, including those involving the safety and performance of the device, and its effect on patients must be examined.
  • All adverse incidents must be fully recorded and notified to the MoH.
  • The written report, signed by the medical practitioner or other authorized person responsible, must contain a critical evaluation of all the data collected during the clinical trial.
  • According to Article 15, the MoH shall, if necessary, take the appropriate steps to ensure public health and public policy. In case the MoH refuses, ceases, suspends, demands significant alteration, it shall inform the European Union Commission. Similarly if the trial is terminated early due to security reasons, the EU Commission shall again be informed. In such way, different from other types of trials, medical device trials are maintained to be monitored in an international platform.

Given the latest developments, it could be stated that the problem related to the legal ground of clinical trials is almost solved. In our opinion, the problems that might arise during the implementation phase, especially related to medical device trials, can be solved by the MoH personnel, researchers and other related persons who are endowed with experience in the field.

However it should be borne in mind that there are still plenty of issues required to be solved by means of general principles of law. For instance, some issues remain unanswered within the scope of the clinical trial related legislation such as preparation of clinical trial protocol and trial reports; protection of clinical trial data; liability and limits of the sponsor, physician and research institution; the scope of damage and liability insurances. Consequently, it seems that all shareholders who take part in clinical trials need to put more effort to understand limits of their responsibilities and liabilities under the related legislation focused to protect human life.


1. The 10th Chamber of Council of State rejected demands of TMA except the volunteers being offered remuneration and being informed by the research team.

2. It is possible for the trials that are falling into responsibilty of "Pharmaceutical" and "Non-Pharmacological" Ethical Committees to be examined by only one Ethical Committee that is to be established as Clinical Rtrials Ethical Committee; however a seperate Ethical Committee shall certainly be established for BA/BE studies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions